Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin

Veterinary Microbiology

Volumn 153, Issue 3-4, 2011, Pages 240-245

  Govendir, M ^a   Norris, J M ^a   Hansen, T ^b   Wigney, D I ^a   Muscatello, G ^a   Trott, D J ^c   Malik, R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Herston Hospitals Complex   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Cat; Dog; Fluoroquinolone; Mycobacteria; Mycobacterium fortuitum; Mycobacterium smegmatis; Nocardia; Pradofloxacin

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFAMANDOLE; CEFOTAXIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ENROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; MINOCYCLINE; PRADOFLOXACIN; QUINOLONE DERIVATIVE; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIUM CULTURE; BROTH DILUTION; CAT; CAT DISEASE; CONTROLLED STUDY; DEHYDRATION; DOG; DOG DISEASE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM SMEGMATIS; NOCARDIA; NOCARDIA FARCINICA; NONHUMAN;

ANIMALS; ANTI-BACTERIAL AGENTS; CAT DISEASES; CATS; CIPROFLOXACIN; DOG DISEASES; DOGS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; NOCARDIA; NOCARDIA INFECTIONS;

CANIS FAMILIARIS; CORYNEBACTERINEAE; FELIDAE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM SMEGMATIS; NOCARDIA; NOCARDIA CYRIACIGEORGICA; NOCARDIA FARCINICA; NOCARDIA NOVA;

EID: 80053132734     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2011.06.001     Document Type: Article

References (28)

1. Boothe D.M., Boeckh A., Simpson R.B., Dubose K. Comparison of pharmacodynamic and pharmacokinetics indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. J. Vet. Intern. Med. 2006, 20:1297-1306.
2. Brown-Elliott B.A., Wallace R.J., Crist C.J., Mann L., Wilson R.W. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob. Agents Chemother. 2002, 46:3283-3285.
3. Bywater R., Silley P., Simjee S. Antimicrobial breakpoints-definitions and conflicting requirements (Letter to the Editor). Vet. Microbiol. 2006, 118:158-159.
4. Chun J., Goodfellow M. A phylogenetic analysis of the genus Nocardia with 16S rRNA gene sequences. Int. J. Syst. Bacteriol. 1995, 45:240-245.
5. CLSI Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Information Supplement. CLSI Document M100-S17 2007, Clinical and Laboratory Standard Institute, Wayne, PA.
6. CLSI Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved standard -Third Edition. CLSI Document M31-A3 2008, Clinical and Laboratory Standards Institute, Wayne, PA.
7. CLSI Susceptibility Testing of Mycobacteria, Nocardiae, and other Aerobic Actinomycetes; Approved standard-Second Edition. CLSI Document M24-A2 2010, Clinical and Laboratory Standards Institute, Wayne, PA.
8. Credito K., Kosowska-Shick K., McGhee P., Pankuch G.A., Appelbaum P.C. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci. Antimicrob. Agent. Chemother. 2010, 52:673-677.
9. Dong Y., Zhao X., Domagala J., Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutant of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agent Chemother. 1999, 43:1756-1758.
10. Drancourt M., Bollet C., Carlioz A., Martelin R., Gayral J.P., Raoult D. 16S ribosomal DNA sequence analysis of a large collection of environmental and clinical unidentifiable bacterial isolates. J. Clin. Microbiol. 2000, 38:3623-3630.
11. Edwards D. Actinomycosis and nocardiosis. Infectious Diseases of the Dog and Cat 2006, 456-461. Elsevier, St. Louis. C. Greene (Ed.).
12. European Medicines Agency, 2007. Refusal CVMP Assessment report for Veraflox. London. Date retrieved 20/12/2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/veterinary/000099/WC500069511.pdf.
13. European Medicines Agency, 2011. Committee for Medicinal Products for Veterinary Use. Summary of opinion-Veroflox, pradofloxacin. London. Date retrieved 18/3/2011. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/veterinary/000159/WC500094738.pdf.
14. Ford M.M., Dubielzig R.R., Giuliano E.A., Moore C.P., Narfstrom K.L. Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats. Am. J. Vet. Res. 2007, 68:190-202.
15. Gelatt K.N., Van-Der-Woerdt A., Ketring K.L., Andrew S.E., Brooks D.E., Biros D.J., Denis H.M., Cutler T.J. Enrofloxacin-associated retinal degeneration in cats. Vet. Ophthalmol. 2001, 4:99-106.
16. Gottlieb S., Wigney D.I., Martin P.A., Norris J.M., Malik R., Govendir M. Susceptibility of canine and feline E. coli and canine Staphylococcus intermedius isolates to veterinary fluoroquinolones and ciprofloxacin. Aust. Vet. J. 2008, 86:148-152.
17. Govendir M., Hansen T., Kimble B., Norris J.M., Baral R.M., Wigney D.I., Gottlieb S., Malik R. Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin. Vet. Microbiol. 2011, 47:113-118.
18. Horne K.S., Kunkle G.A. Clinical outcome of cutaneous rapidly growing mycobacterial infections in cats in the south-eastern United States: a review of 10 cases (1996-2006). J. Feline Med. Surg. 2009, 11:627-632.
19. Lunn J.A., Martin P., Zaki S., Malik R. Pneumonia due to Mycobacterium abscessus in two domestic ferrets (Mustelo putorius furo). Aust. Vet. J. 2005, 83:542-546.
20. Malik R., Krockenberger M.B., O'Brien C.R., White J.D., Foster D., Tisdall P.L.C., Gunew M., Carr P.D., Bodell L., McCowan C., Howe J., Oakley C., Griffin C., Wigney D.I., Martin P., Norris J., Hunt G., Mitchell D.H., Gilpin C. Nocardia infections in cats: a retrospective multi-institutional study of 17 cases. Aust. Vet. J. 2006, 84:235-245.
21. Malik R., Shaw S.E., Griffin C., Stanley B., Burrows A.K., Bryden S.L., Titmarsh J., Stutsel M.J., Carter S.A., Warner A., Martin P., Wigney D.I., Gilpin C. Infections of the subcutis and skin of dogs caused by rapidly growing mycobacteria. J. Small Anim. Pract. 2004, 45:485-494.
22. Malik R., Wigney D.I., Dawson D., Martin P., Hunt G.B., Love D.N. Infection of the subcutis and skin or cats with rapidly growing mycobacteria: a review of microbiological and clinical findings. J. Feline Med. Surg. 2000, 2:35-48.
23. Messias A., Gekeler F., Wegener A., Dietz K., Kohler K., Zrenner E. Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography. Doc. Ophthalmol. 2008, 116:177-191.
24. Muscatello G., Browning G.F. Identification and differentiation of avirulent and virulent Rhodococcus equi using selective media and colony blotting DNA hybridization to determine their concentrations in the environment. Vet. Microbiol. 2004, 100:121-127.
25. Schwarz S., Silley P., Simjee S., Woodford N., van-Duijkeren E., Johnson A.P., Gaastra W. Assessing the antimicrobial susceptibility of bacteria obtained from animals. Vet. Microbiol. 2010, 141:1-4.
26. Stass H., Kubitza D., Schuhly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin. Pharmacokinet. 2001, Suppl. 40:1-9.
27. Stephan B., Greife H.A., Pridmore A., Silley P. Activity of pradofloxacin against Porphyromonas and Prevotella spp. Implicated in periodontal disease in dogs: susceptibility test data from a European multicenter study. Antimicrob. Agents Chemother. 2008, 52:2149-2155.
28. Wetzstein H.G. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob. Agent. Chemother. 2005, 49:4166-4173.